Entera Bio Ltd
NASDAQ:ENTX
Entera Bio Ltd
Cost of Revenue
Entera Bio Ltd
Cost of Revenue Peer Comparison
Competitive Cost of Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Entera Bio Ltd
NASDAQ:ENTX
|
Cost of Revenue
$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Collplant Biotechnologies Ltd
NASDAQ:CLGN
|
Cost of Revenue
-$1.1m
|
CAGR 3-Years
28%
|
CAGR 5-Years
7%
|
CAGR 10-Years
N/A
|
|
Kamada Ltd
NASDAQ:KMDA
|
Cost of Revenue
-$87m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-7%
|
|
B
|
BioLine RX Ltd
TASE:BLRX
|
Cost of Revenue
-$3.7m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
Urogen Pharma Ltd
NASDAQ:URGN
|
Cost of Revenue
-$9.4m
|
CAGR 3-Years
-110%
|
CAGR 5-Years
-39%
|
CAGR 10-Years
N/A
|
|
B
|
Bonus Biogroup Ltd
TASE:BONS
|
Cost of Revenue
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Entera Bio Ltd's Cost of Revenue?
Cost of Revenue
0
USD
Based on the financial report for Dec 31, 2023, Entera Bio Ltd's Cost of Revenue amounts to 0 USD.